Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Eylea

 
National Institutes of Health

Related topics

Related topics

3 relations
0.05 ML aflibercept 40 MG/ML Injection [Eylea]aflibercept Injection [Eylea]

Broader (1)

aflibercept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA.
PURPOSE To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic… Expand
2019
2019
Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.
Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought… Expand
2019
2019
Eylea (Aflibercept) Injection Approved for Diabetic Retinopathy
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor. 
2018
2018
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
Effect of intravitreal aflibercept (Eylea®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration
PurposeTo investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients… Expand
  • table 1
  • table 2
2017
2017
Efficacy of aflibercept (EYLEA®) on inhibition of human VEGF in vitro.
INTRODUCTION Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several… Expand
  • figure 1
  • figure 2
2016
2016
Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
PURPOSE We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2016
2016
Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that… Expand
  • figure 1
  • figure 2
  • figure 3
2016
2016
Including off-label drug indications in HTA jeopardizes patient health and discourages innovation
Anti-VEGF Drugs Anti-VEGF drugs are used to treat retinal conditions such as the wet form of age-related macular degeneration… Expand
2014
2014
Ocular distribution and pharmacokinetics of 125I‐OPT302 and 125I‐Aflibercept (EYLEA) following intravitreal administration to pigmented rabbits
Purpose OPT‐302 is a soluble receptor that specifically and potently blocks VEGF‐C and VEGF‐D activity which are involved in the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE